SCYNEXIS to Present Data from the CANDLE Nested Sub-Study of Ibrexafungerp During the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease Update
JERSEY CITY, N.J., July 14, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to...
Cellbxhealth PLC Announces Holding(s) in Company